Drug Profile
Cotadutide - AstraZeneca
Alternative Names: MEDI 0382Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca; MedImmune
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Glucagon receptor agonists; Glucagon-like peptide 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Liver disorders; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 02 Oct 2023 Efficacy and adverse events data from a phase II trial in Type II diabetes mellitus presented at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD-2023)
- 05 Apr 2023 Discontinued - Phase-I for Liver disorders in USA (SC) (NCT05668936)
- 05 Apr 2023 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Germany (SC) (NCT05668936)